top of page

Drug Target Review features an insightful article by Dan Williams that explores the extraordinary achievements of AI in drug design

Dr Dan Williams
Dec 4, 2025
1 min read

Dan Williams imagines a future where new drugs, that cause no side effects and don't need to go through clinical trials, can be created at the push of a button. Read the full article in Drug Target Review:

https://www.drugtargetreview.com/article/190739/steam-to-ai-drug-innovation/

Dr Dan Williams, SynaptixBio

Recent Posts

Dr Uwe Meya, SynaptixBio’s CMO

Technology Networks features a major interview with Dr Uwe Meya, SynaptixBio’s CMO, in which the issues around organising, funding, and conducting clinical trials for rare diseases are discussed.

Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis

Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis

SynaptixBio - Mother & Child

Dan Williams welcomes news that NICE has raised the cost-effectiveness threshold for ultra-rare disease drugs

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.

bottom of page